QT Vascular downplays competitor’s patent claim

It will not affect the group’s profitability.

QT Vascular today reiterated its stance that the patent infringement claim filed against the company will not have a material effect on its financial position or profitability.

Its challenger, specialty balloon angioplasty company AngioScore, alleged that QT Vascular’s Chocolate PTA infringes the ‘119 Patent, a patent that claims a very specific design for an angioplasty balloon catheter and a non-deployable stent.

QT Vascular today stated that there is a “minimal” probability that AngioScore could obtain a permanent injunction against the Chocolate PTA because AngioScore does not practice the ’119 Patent

The group further stated that a new available design of Chocolate PTA will materially reduce the risks related to the patent claim on Chocolate PTA.

QT Vascular noted that the patent claim does not implicate intellectual property and the Group is not at risk of losing intellectual property including patent applications as a consequence of the claim.